NuvectisPharma_Logos_FINAL_Full_Color.png
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
March 19, 2024 08:00 ET | Nuvectis Pharma, Inc.
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
NuvectisPharma_Logos_FINAL_Full_Color.png
Nuvectis Pharma to Present at the 36th Annual Roth Conference
March 15, 2024 08:00 ET | Nuvectis Pharma, Inc.
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
NuvectisPharma_Logos_FINAL_Full_Color.png
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
March 14, 2024 09:00 ET | Nuvectis Pharma, Inc.
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a...
NuvectisPharma_Logos_FINAL_Full_Color.png
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
March 05, 2024 08:00 ET | Nuvectis Pharma, Inc.
NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the FDANXP800...
NuvectisPharma_Logos_FINAL_Full_Color.png
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
February 09, 2024 08:32 ET | Nuvectis Pharma, Inc.
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
NuvectisPharma_Logos_FINAL_Full_Color.png
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
February 09, 2024 08:00 ET | Nuvectis Pharma, Inc.
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
NuvectisPharma_Logos_FINAL_Full_Color.png
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:00 ET | Nuvectis Pharma, Inc.
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
NuvectisPharma_Logos_FINAL_Full_Color.png
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
December 18, 2023 08:00 ET | Nuvectis Pharma, Inc.
Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by...
NuvectisPharma_Logos_FINAL_Full_Color.png
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
November 08, 2023 08:00 ET | Nuvectis Pharma, Inc.
Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid...
NuvectisPharma_Logos_FINAL_Full_Color.png
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
October 24, 2023 08:00 ET | Nuvectis Pharma, Inc.
Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...